These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 37522891)

  • 1. The pharmacokinetic-pharmacodynamic modelling framework as a tool to predict drug resistance evolution.
    Witzany C; Rolff J; Regoes RR; Igler C
    Microbiology (Reading); 2023 Jul; 169(7):. PubMed ID: 37522891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-step vs. single-step resistance evolution under different drugs, pharmacokinetics, and treatment regimens.
    Igler C; Rolff J; Regoes R
    Elife; 2021 May; 10():. PubMed ID: 34001313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic pharmacokinetic/pharmacodynamic modelling: MIC, pharmacodynamic indices and beyond.
    Rao GG; Landersdorfer CB
    Int J Antimicrob Agents; 2021 Aug; 58(2):106368. PubMed ID: 34058336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects.
    Minichmayr IK; Aranzana-Climent V; Friberg LE
    Int J Antimicrob Agents; 2022 Sep; 60(3):106616. PubMed ID: 35691605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semi-mechanistic pharmacokinetic-pharmacodynamic modelling of antibiotic drug combinations.
    Brill MJE; Kristoffersson AN; Zhao C; Nielsen EI; Friberg LE
    Clin Microbiol Infect; 2018 Jul; 24(7):697-706. PubMed ID: 29229429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the relative importance of bacterial resistance, persistence and hyper-mutation for antibiotic treatment failure.
    Witzany C; Regoes RR; Igler C
    Proc Biol Sci; 2022 Nov; 289(1986):20221300. PubMed ID: 36350213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial Resistance in Bacteria: Mechanisms, Evolution, and Persistence.
    Christaki E; Marcou M; Tofarides A
    J Mol Evol; 2020 Jan; 88(1):26-40. PubMed ID: 31659373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs.
    Nielsen EI; Friberg LE
    Pharmacol Rev; 2013 Jul; 65(3):1053-90. PubMed ID: 23803529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological units of antimicrobial resistance and strategies for their containment in animal production.
    Muurinen J; Cairns J; Ekakoro JE; Wickware CL; Ruple A; Johnson TA
    FEMS Microbiol Ecol; 2022 Jul; 98(7):. PubMed ID: 35587376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials.
    Li RC; Zhu M; Schentag JJ
    Clin Pharmacokinet; 1999 Jul; 37(1):1-16. PubMed ID: 10451780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.
    Slavik RS; Jewesson PJ
    Clin Pharmacokinet; 2003; 42(9):793-817. PubMed ID: 12882587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting drug resistance evolution: insights from antimicrobial peptides and antibiotics.
    Yu G; Baeder DY; Regoes RR; Rolff J
    Proc Biol Sci; 2018 Mar; 285(1874):. PubMed ID: 29540517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial-induced horizontal transfer of antimicrobial resistance genes in bacteria: a mini-review.
    Liu G; Thomsen LE; Olsen JE
    J Antimicrob Chemother; 2022 Feb; 77(3):556-567. PubMed ID: 34894259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.
    Hyatt JM; McKinnon PS; Zimmer GS; Schentag JJ
    Clin Pharmacokinet; 1995 Feb; 28(2):143-60. PubMed ID: 7736689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology.
    Barker CI; Germovsek E; Hoare RL; Lestner JM; Lewis J; Standing JF
    Adv Drug Deliv Rev; 2014 Jun; 73(100):127-39. PubMed ID: 24440429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetic/pharmacodynamic analysis in microbiology: a tool for the evaluation of the antimicrobial treatment].
    Canut Blasco A; Aguilar Alfaro L; Cobo Reinoso J; Giménez Mestre MJ; Rodríguez-Gascón A
    Enferm Infecc Microbiol Clin; 2015 Jan; 33(1):48-57. PubMed ID: 23850188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.
    Nielsen EI; Cars O; Friberg LE
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4619-30. PubMed ID: 21807983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive laboratory evolution of antimicrobial resistance in bacteria for genetic and phenotypic analyses.
    Vinchhi R; Jena C; Matange N
    STAR Protoc; 2023 Mar; 4(1):102005. PubMed ID: 36625217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance.
    Adembri C; Novelli A
    Clin Pharmacokinet; 2009; 48(8):517-28. PubMed ID: 19705922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications for antimicrobial prescribing of strategies based on bacterial eradication.
    Klugman KP
    Int J Infect Dis; 2003 Mar; 7 Suppl 1():S27-31. PubMed ID: 12839705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.